Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 17/20 | 0.42 |
| ▸ | HRH1 | P35367 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3649162 | 1.00 | HRH3 (0.42) | HRH3HRH1KMT2AKCNH2MEN1 | |
| SCHEMBL4019372 | 0.92 | MAPK1 (0.46) | HRH3HRH1KMT2AKCNH2MEN1 | |
| SCHEMBL3644099 | 0.92 | MAPK1 (0.46) | HRH3HRH1KMT2AKCNH2MEN1 | |
| SCHEMBL4015462 | 0.88 | HRH3 (0.43) | HRH3KMT2ACYP2D6 | |
| SCHEMBL4015459 | 0.88 | HRH3 (0.43) | HRH3KMT2ACYP2D6 | |
| SCHEMBL3809361 | 0.88 | HRH3 (0.46) | HRH3HRH1KMT2AKCNH2MEN1 | |
| SCHEMBL3647764 | 0.87 | HRH3 (0.45) | HRH3HRH1KMT2AKCNH2MEN1 | |
| SCHEMBL4017332 | 0.87 | RECQL (0.36) | HRH3HRH1KMT2AMEN1CYP2D6 | |
| SCHEMBL4017336 | 0.87 | RECQL (0.36) | HRH3HRH1KMT2AMEN1CYP2D6 | |
| SCHEMBL3645318 | 0.86 | HRH3 (0.45) | HRH3HRH1KMT2AKCNH2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7534788-B2 | Benzofuran and benzothiophene-2-carboxylic acid amide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-05-19 | — | — | US | claimed |
| US-20090029976-A1 | BENZOFURAN AND BENZOTHIOPHENE-2-CARBOXYLIC ACID AMIDE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2009-01-29 | — | — | US | claimed |
| US-7534788-B2 | Benzofuran and benzothiophene-2-carboxylic acid amide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-05-19 | — | — | US | disclosed |
| US-20090029976-A1 | BENZOFURAN AND BENZOTHIOPHENE-2-CARBOXYLIC ACID AMIDE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029976-A1 | BENZOFURAN AND BENZOTHIOPHENE-2-CARBOXYLIC ACID AMIDE DERIVATIVES | HCAR2, HCAR1, HRH3 | HRH3 3/4885HRH1 8/4885KMT2A 231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.